Citi Raises Q3 Estimates On Hospira (HSP)

Citi Investment Research is raising its earnings estimates on Hospira (NYSE: HSP). It has a Sell/High Risk rating on shares, and a $52 price target.

In a note to clients, Citi writes, "The challenges facing HSP's Specialty Injectable (SIP) and Infusion Pump (MMS) businesses should largely be offset in 3Q by another benefit from Oxaliplatin and a favorable shift in FX. We are moving 3Q EPS up $0.05 to $0.71 to reflect these changes with no revisions to our forward estimates."

Shares of HSP gained 11 cents yesterday to close at $58.42.

Don't miss these trading ideas!